Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume -, Issue -, Pages 1-16
Publisher
Informa UK Limited
Online
2018-07-21
DOI
10.1080/14760584.2018.1495565
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
- (2017) Katrijn Grupping et al. JOURNAL OF INFECTIOUS DISEASES
- Intramuscularly administered herpes zoster subunit vaccine has no effects on fertility, pre- and post-natal development in Sprague-Dawley rats
- (2017) Lawrence Segal et al. REPRODUCTIVE TOXICOLOGY
- The temporal impact of aging on the burden of herpes zoster
- (2017) Lijoy Varghese et al. BMC Geriatrics
- Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial
- (2017) Lidia Oostvogels Open Forum Infectious Diseases
- Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
- (2017) Karlis Pauksens et al. Open Forum Infectious Diseases
- Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity
- (2017) Margherita Coccia et al. npj Vaccines
- Herpes zoster and the search for an effective vaccine
- (2016) N. Arnold et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Impact of adjuvants on CD4 + T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
- (2016) Geert Leroux-Roels et al. CLINICAL IMMUNOLOGY
- Adjuvant system AS01: helping to overcome the challenges of modern vaccines
- (2016) Arnaud M. Didierlaurent et al. Expert Review of Vaccines
- Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits
- (2016) Giulia Giordano et al. JOURNAL OF APPLIED TOXICOLOGY
- Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years
- (2016) Hung Fu Tseng et al. JOURNAL OF INFECTIOUS DISEASES
- European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment
- (2016) R.N. Werner et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
- (2016) Anthony L. Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccine safety evaluation: Practical aspects in assessing benefits and risks
- (2016) Alberta Di Pasquale et al. VACCINE
- Vaccine provision: Delivering sustained & widespread use
- (2016) Scott Preiss et al. VACCINE
- Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
- (2016) Roman Chlibek et al. VACCINE
- Vaccine development: From concept to early clinical testing
- (2016) Anthony L. Cunningham et al. VACCINE
- Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
- (2016) Michel Fochesato et al. Human Vaccines & Immunotherapeutics
- From discovery to licensure, the Adjuvant System story
- (2016) Nathalie Garçon et al. Human Vaccines & Immunotherapeutics
- Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly
- (2016) Peter Vink et al. Human Vaccines & Immunotherapeutics
- Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination
- (2016) Huifeng Yun et al. Arthritis & Rheumatology
- Immunogenicity and Safety of 2 Doses of an Investigational Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Adults 50 Years and Older: Results of a Phase III, Randomized, Open-Label, Multicenter Trial
- (2016) Airi Poder et al. Open Forum Infectious Diseases
- Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies
- (2016) Janet E. McElhaney et al. Open Forum Infectious Diseases
- Randomized, Phase III Clinical Trial to Assess the Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine Co-Administered With a Seasonal Quadrivalent-Inactivated Influenza Vaccine in Adults Aged 50 Years and Older
- (2016) Tino F. Schwarz et al. Open Forum Infectious Diseases
- Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01
- (2016) Sophie Detienne et al. Scientific Reports
- The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review
- (2015) Adam Gater et al. BMC PUBLIC HEALTH
- Herpes zoster-associated mortality in Europe: a systematic review
- (2015) Hélène Bricout et al. BMC PUBLIC HEALTH
- Varicella zoster virus immunity: A primer
- (2015) Christopher J.A. Duncan et al. JOURNAL OF INFECTION
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- (2015) Himal Lal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety assessment of adjuvanted vaccines: Methodological considerations
- (2015) Fernanda Tavares Da Silva et al. Human Vaccines & Immunotherapeutics
- A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
- (2014) E. A. Stadtmauer et al. BLOOD
- Long-term Persistence of Zoster Vaccine Efficacy
- (2014) Vicki A. Morrison et al. CLINICAL INFECTIOUS DISEASES
- Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells
- (2014) Arnaud M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
- Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
- (2014) Elchonon M. Berkowitz et al. JOURNAL OF INFECTIOUS DISEASES
- Complications of herpes zoster in cancer patients
- (2014) Trung N. Tran et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study
- (2014) Roman Chlibek et al. VACCINE
- Systematic review of incidence and complications of herpes zoster: towards a global perspective
- (2014) K. Kawai et al. BMJ Open
- Natural killer cell deficiency
- (2013) Jordan S. Orange JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A population based study of the epidemiology of Herpes Zoster and its complications
- (2013) Dahlia Weitzman et al. JOURNAL OF INFECTION
- Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age
- (2013) R. Chlibek et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults
- (2013) Kathleen M. Mullane et al. JOURNAL OF INFECTIOUS DISEASES
- Incidence and Clinical Characteristics of Herpes Zoster Among Children in the Varicella Vaccine Era, 2005–2009
- (2013) Sheila Weinmann et al. JOURNAL OF INFECTIOUS DISEASES
- The global epidemiology of herpes zoster
- (2013) B. P. Yawn et al. NEUROLOGY
- Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines
- (2013) Fernanda Tavares Da Silva et al. VACCINE
- Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)
- (2013) Himal Lal et al. Human Vaccines & Immunotherapeutics
- Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study
- (2013) Sinéad M. Langan et al. PLOS MEDICINE
- The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer
- (2012) L. A. Habel et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Herpes Zoster-Related Deaths in the United States: Validity of Death Certificates and Mortality Rates, 1979-2007
- (2012) A. Mahamud et al. CLINICAL INFECTIOUS DISEASES
- Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy
- (2012) K. E. Schmader et al. CLINICAL INFECTIOUS DISEASES
- Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
- (2012) K. E. Schmader et al. CLINICAL INFECTIOUS DISEASES
- A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults
- (2012) Isabel Leroux-Roels et al. JOURNAL OF INFECTIOUS DISEASES
- Sampling of herpes zoster skin lesion types and the impact on viral DNA detection
- (2012) Johann F. Mols et al. JOURNAL OF VIROLOGICAL METHODS
- Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: A 6-month prospective study
- (2012) Mélanie Drolet et al. VACCINE
- Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice
- (2012) Najoua Dendouga et al. VACCINE
- Herpes zoster in Germany: Quantifying the burden of disease
- (2011) Bernhard Ultsch et al. BMC INFECTIOUS DISEASES
- Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
- (2011) Nathalie Garçon et al. Expert Review of Vaccines
- Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
- (2010) Leonardo Emberti Gialloreti et al. BMC INFECTIOUS DISEASES
- Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors
- (2010) G. N. Malavige et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Zoster Vaccine: Current Status and Future Prospects
- (2010) Michael N. Oxman CLINICAL INFECTIOUS DISEASES
- Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine
- (2009) Adriana Weinberg et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
- (2009) Kent E. Kester et al. JOURNAL OF INFECTIOUS DISEASES
- Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection
- (2009) B. Berarducci et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine
- (2008) M. J. Levin et al. JOURNAL OF INFECTIOUS DISEASES
- Humoral and Cellular Immunity to Varicella‐Zoster Virus: An Overview
- (2008) Ann M. Arvin JOURNAL OF INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started